Keywords:

the e a e   e   d   h ch ed   a e   he a e f   g ch   a e   ed c   f PTC   cc   e ce   HT a e   ha   ad e e f   g ea   h   dec   HT ca e   h h gh   f   g e   PTC be f e   cc   e ce ha b e e   dec ea e he a g a c   ch a e .

 e ef e, ea ed   he e e   d   e a a e he ef e   f   g a a e f he   e   ea d ec c a e f   a a   h   d ca c   a, a e   e   ed, e.g. CD56, HBME-1 a d CK-19 d d a a d   c   b a ,   de ec he ab   d e e   a e HT f   PTC a d de ec he a e   ed c   f   a g a   g e   f ce a ca e f HT   PTC.

Patients and Methods

I he   e d be ee Ja a   2012 a d Dece be   f 2016, 200 c   ec   e a e   h e he   a h   d   d e   d a g e   de e   a h   dec   ge e a   ge   h   a ,   c   g   , fac   f   ed c e Zagazig U   e

c⬦ a ed g Ch - a ee ⬦ F he' e ac e he a ⬦ a e.
Pa ed ca eg⬦ ca a ab e e e c⬦ a ed g McNe a' e .
A e e e ⬦ ded. P- a e <0.05 a c⬦ de ed a ca ⊠
g ca . Va d ⊠ IHC a ca c a ed g d ag ⬦ c e f⬦ a c e
de e d ⬦ a e 2 2 c⬦ ge c ⊠ ab e ge e a ⬦ g he
h ⬦⬦ g ca e a a ⬦ a he efe e ce (G⬦ d) a da d. e
e e , ec c e , ⬦ e ed c e a e , ega e ed c e
Wed. d. 55 T -3e ⊠ A h d)]TJ g ⬦ 2⬦ 1.83 Td(2.d .)T T

d ag ⬦ ed a f⬦ c a a a ⬦ f PTC a d 18 ca e e e d ag ⬦ ed
a C a c PTC, 20 ca e ⬦ f PTC h⬦ e ⬦ h ⬦ ⊠ ⬦ f HT he ⊠
ha e c ded 4 a e a d 16 fe a e , h he age a ged f⬦
35-50 ⊠ea ⬦ d, 3 ca e e e ac ⬦ c⬦ ca ⊠ e e ed h d e
g⬦ e a d 17 e e ed h c⬦ d ⬦ a ⊠ h⊠ ⬦ d ⬦ d e , 4 ca e e e
d ag ⬦ ed a f⬦ c a a a ⬦ f PTC a d 16 ca e e e d ag ⬦ ed a
C a c PTC a d 30 ca e ha ha e a d ag ⬦ ed a HT he ⊠ ha e
e d c ded 4 a e a d 26 fe a e , h he age a ged f⬦ '25-35
⊠ea ⬦ d, 25 ca e e e ac ⬦ c⬦ ca ⊠ e e ed h d e g⬦ e
a d 5 e e ed h ⬦ a ⊠ h ⊠ ⬦ d ⬦ d e.

A a e a e c⬦ ⬦ ed ⬦ f 10 (14%) a e a d 60(86%) fe a e
h age a ged f⬦ 29-51 ⊠ea f⬦ a e h PTC h h ⬦ ⊠ ⬦ f
HT, 29-52 ⊠ea f⬦ a e h PTC h⬦ h ⬦ ⊠ ⬦ f HT a d 22-40
⊠ea f⬦ a e h HT.

1. F g⬦ 20 a a b⬦ c ⬦ f ⬦ a h ⊠ ⬦ dec⬦ ⊠ ec e
ha e e ce ⊠ d ag ⬦ ed a PTC, c ded 2 (10%) a e a d
18(90%) fe a e .

2. 2 ᵈ g⬦ 20 a a b⬦ c ⬦ f he a e ca e h ⬦ ca ⊠
d ag ⬦ ed a HT b ⊠ b ⬦ a h ⊠ ⬦ dec⬦ ⊠ ce a ab e e ⬦ d .

Citation: Harb OA (2017) Value of CD56, HBME-1, and CK19 Expression in Predicting the Risk of Papillary Thyroid Carcinoma (PTC) Occurrence in Hashimoto's Thyroiditis (HT) Patients. J Oncol Res Treat 2: 117.

Page 4 of 9

3. 3ʳᵈ group 30 aa bᵒc ᵒf ᵃ a hᵒᵒdecᵒ ᵒec e ha ha e e ece dag ed a HT. c ded 3 (10%) a e a d 27(90%) fe a e.

4. 4ᵗʰ g ᵒ 30 a a bᵒc ᵒf he a e ca e hᵒ ᵒca d ag ed a HT b b a hᵒᵒdec ce a ab e e ᵒd.

5. 5ᵗʰ g ᵒ 20 a a bᵒc ᵒf ha e e d ag ed a PTC hᵒ e ᵒ h ᵒᵒf HT. c ded 5 (25%) a e a d 15 (75%) fe a e.

Immuno-histochemical expression in the studied thyroid: 1-CD56 e e ᵒ he d e e ᵒ: A ᵒg he g ᵒ, ega e CD56 e e ᵒ a de ec ed 16 (80%), fᵒca ᵒ e CD56 e e ᵒ a ᵒbe ed 2 (10%) a d d e ᵒ e CD56 e e ᵒ a fᵒ d 2 (10%) ᵒf ca e ᵒf PTC ha a ᵒ ᵒ ᵒf HT (Tab e 1, 2, F g e 1E, 1F, 2E a d 3C).

A ᵒg he ec ᵒ d g ᵒ, ega e CD56 e e ᵒ a de ec ed 10 (50%), fᵒca ᵒ e CD56 e e ᵒ a ᵒbe ed 8 (40%) a d d e ᵒ e CD56 e e ᵒ a fᵒ d 2(10%) ᵒf ca e ᵒf HT ha fᵒ d ᵒ a fᵒ ed ᵒ PTC a e ᵒ. Ca e h FED e e a ega e fᵒ CD56.

A ᵒg he h d g ᵒ, ega e CD56 e e ᵒ a de ec ed 5 (16.7%), fᵒca ᵒ e CD56 e e ᵒ a ᵒbe ed 12 (40%) a d d e ᵒ e CD56 e e ᵒ a fᵒ d 13 (43.3%) ᵒf ca e ᵒf HT ha a ᵒ a fᵒ ed ᵒ PTC a e ᵒ.

A ᵒg he 4 h g ᵒ, ega e CD56 e e ᵒ a de ec ed 5 (16.7%), fᵒca ᵒ e CD56 e e ᵒ a ᵒbe ed 12 (40%) a d d e ᵒ e CD56 e e ᵒ a fᵒ d 13 (43.3%) ᵒf ca e ᵒf HT ha a ᵒ a fᵒ ed ᵒ PTC a e ᵒ.

A ᵒg he 5ᵗʰ g ᵒ, ega e CD56 e e ᵒ a de ec ed 17 (85%), fᵒca ᵒ e CD56 e e ᵒ a ᵒbe ed 2 (10%) a d d e ᵒ e CD56 e e ᵒ a fᵒ d 1 (5%) ᵒf ca e ᵒf PTC h ᵒh ᵒᵒf HT.

2-HBME-1 e e ᵒ he d ed e ᵒ HBME-1 g a a de ec ed ed ᵒ a he c ᵒ a (Tab e 1, 3, F g e 1A, 1B, 2A, 2B a d 3A).

A ᵒg he g ᵒ, ega e HBME-1 e e ᵒ a de ec ed 2 (10%), fᵒca ᵒ e HBME-1 e e ᵒ a ᵒbe ed 4 (20%) a d d e ᵒ e HBME-1 e e ᵒ a fᵒ d 14 (70%) ᵒf ca e ᵒf PTC ha a ᵒ ᵒ ᵒf HT.

A ᵒg he ec ᵒ d g ᵒ, ega e HBME-1 e e ᵒ a de ec ed 4 (20%), fᵒca ᵒ e HBME-1 e e ᵒ a ᵒbe ed

8 (40%) a d d e ᵒ e HBME-1 e e ᵒ a fᵒ d 8 (40%) ᵒf ca e ᵒf HT ha fᵒ d ᵒ a fᵒ ed ᵒ PTC a e ᵒ, a d 4 ca e ᵒf hᵒ e hd e ᵒ ee e ᵒ ᵒf HMBE1 ca ed fᵒc ᵒf FED.

A ᵒg he h d g ᵒ, ega e HBME-1 e e ᵒ a de ec ed 22 (73.3%), fᵒca ᵒ e HBME-1 e e ᵒ a ᵒbe ed 7 (23.3%) a d d e ᵒ e HBME-1 e e ᵒ a fᵒ d 1 (3.3%) ᵒf ca e ᵒf HT ha a ᵒ a fᵒ ed ᵒ PTC a e ᵒ.

A ᵒg he 4 h g ᵒ, ega e HBME-1 e e ᵒ a de ec ed 22 (73.3%), fᵒca ᵒ e HBME-1 e e ᵒ a ᵒbe ed 7 (23.3%) a d d e ᵒ e HBME-1 e e ᵒ a fᵒ d 1 (3.3%) ᵒf ca e ᵒf HT ha a ᵒ a fᵒ ed ᵒ PTC a e ᵒ.

A ᵒg he 5 h g ᵒ, ega e HBME-1 e e ᵒ a de ec ed 3 (15%), fᵒca ᵒ e HBME-1 e e ᵒ a ᵒbe ed 6 (30%)

(a)　　　(b)

(c)　　　(d)

(e)

a d d   e ❧   e HBME-1 e   e ❧   a f❧   d   11 (55%) ❧f ca e
❧f PTC   ħ ❧ħ   ❧ ☒❧f HT.

HT ha f d a f ed PTC a e , 2 ca e f h e h f ca e CK19 e e a d 4 ca e f h e h d e e CK19 e e ca ed f c f FED.

A g he h d g , ega e CK19 e e a de ec ed 21 (70%), f ca e CK19 e e a b e ed 7 (23.3%) a d d e e CK19 e e a f d 2 (6.7%) f ca e f HT ha a a f ed PTC a e .

Nega e CK19 e e a de ec ed 21 (70%), f ca e CK19 e e a b e ed 7 (23.3%) a d d e e CK19 e e a f d 2 (6.7%) f ca e f HT ha a a f ed PTC a e . A g he 5 h g , ega e CK19 e e a de ec ed 5 (25%), f ca e CK19 e e a b e ed 4 (20%) a d d e e CK19 e e a f d 11 (55%) f ca e f PTC h h f HT (F g e 4).

N a ca g ca d e e ce a f d be ee (1 a d

5 h g), (2 d a d 5 h g), (3 d a d 4 h g) a ega d a a e e e a d (1 a d 2 d g) a ega d CD56 a d CK19 e e .

e e a h gh g ca a ca d e e ce a f d be ee 2 d a d 4 h g a ega d CD56, HMBE1 a d CK19 e e (P=0.012, 0.000 e ec e).

e e a g ca a ca d e e ce a f d be ee 1

Citation: Harb OA (2017) Value of CD56, HBME-1, and CK19 Expression in Predicting the Risk of Papillary Thyroid Carcinoma (PTC) Occurrence in Hashimoto's Thyroiditis (HT) Patients. J Oncol Res Treat 2: 117.

Page 7 of 9

 e [25]. I   a f d ha ee a ed e e f TSH   HT a e   c d
be a be g   fac   f ca ce [26].

S   a   e   e ea c he   ha e   ed   d e e   a e PTC
f   HT b   h c he   a d ha e   cceeded   ch   e
    g ce a a a ab e e   e a d ec c a e , b he e a e
 e   d   ed e ch   h c he ca   a e
 ed c he   ge   f HT PTC,   ch c   d de   f ag   f
 a e   ha   be a ce a   eed d ea   a h   dec
f   a age e   f HT a d   a g a   a f a   PTC
 a e   .

CD56 ha bee f d   be e a ed   f c a e he
d ee a   , a d   a   e   a h   e   ed h gh CD56
 e e   a   e a c h   d   e a d   e be g
 h   d e   [13,27]. I acc da ce   h h e   d e , ec e
 e a h gh   e CD56 e e   (83.3%) f HT ca e ha
f d   a f   PTC. O he he ha d, ega e CD56
 e e   a be ed   80-85% f PTC ha ha   cc ed   f
HT a d ha ha   cc ed de   e ec e   a d e ha e de ec ed

Citation: Harb OA (2017) Value of CD56, HBME-1, and CK19 Expression in Predicting the Risk of Papillary Thyroid Carcinoma (PTC) Occurrence in Hashimoto's Thyroiditis (HT) Patients. J Oncol Res Treat 2: 117.

Page 8 of 9

... the background and natural history of PTC occurring in HT [40]. So of these data needed to be read carefully here.

Important:

1. ... the histopathological PTC and the co... the natural history of the histopathological HT.

2. ... a statistical and pathological change can be seen both in HT and PTC ... co... era.

3. Data and co... suggested ... described that there are a ... between histopathological ... and ... the, there are a ... co... ... regarding ... ch... e.

4. Management of HT are ... co... there are and ... for ... g a histopathological ... refer added ... there ... occurrence of ... a... ... and the histopathological and lead ... e diagnostic ... ec...

5. Although there are a ... de ... that described the ... diagnosis ... of ... ... ge... a... HT ... g ea... histopathological ... a co... e are a method for the management.

6. It ... should be better care ... a... a... ab be ... are ... ed ... hich case of HT ... that are a high ab... of ... ge ... ... PTC that ... be the f ... e f ... g ea... histopathological ... f ... the are ... ee f ... a... ed g ee... a ed e... e ...

7. We ... ed b ... a... there are e ged f ... d ee... a ... be ee... be g a d a g a histopathological ... e. g. CD56, HBME-1, and CK19.

8. M ... de ha... e a... ed there ... e of ... ch a... e ... PTC d ag... ... d g h HT f ... PTC, b ... e ... ced that there a... e ... e ... d ... h ch ... ed ... a ... e the a... e of ... g ch... a... e... ed co... of PTC occ... e... ce HT a... e ... ha... ad... e e f ... g ea... histopathological ... HT ca... e ... h h gh

30. Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, et al. (2003) HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 50: 173-177.

31. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL (2006) Immunohis-tochemical markers in diagnosis of papillary thyroid carcinoma:utility of HBME 1 combined with CK-19 immunostaining. Mod Pathol 19: 1631-1637

32. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohis-tochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14: 338-342.

33. Song Q, Wang D, Lou Y, Li C, Fang C, et al. (2011) Diagnostic signifcance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol 6: 126.

34. Chung SY, Park ES, Park SY, Song JY, Ryu HS (2014) CXC motif ligand 12 as a novel diagnostic marker for papillary thyroid carcinoma. Head Neck 36: 1005-1012.

35. Wu G, Wang J, Zhou Z, Li T, Tang F (2013) Com-bined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specifcity? J Int Med Res 41: 975-983.

36. Zhu X, Sun T, Lu H, Zhou X, Lu Y, et al. (2010) Diagnostic signifcance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol 63: 786-789.

37. Sahoo S, Hoda SA, Rosai J, DeLellis RA (2001) Cytokeratin 19 immunoreac-tivity in the diagnosis of papillary thyroid carcinoma. Am J Clin Pathol 116: 696-702.

38. Guyetant S, Michalak S, Valo I, Saint-André JP(immun3)Dagnosisg,iDeLellis g DeLellis